Prostate cancer | Page 14 of 18

Prostate Cancer :: Aging gene also protects against prostate cancer development

Cancer researchers have found that a gene that is involved in regulating aging also blocks prostate cancer cell growth. They have shown that the enzyme SIRT1 can block the growth of treatment-resistant prostate cancer cells that overexpress a mutation for the androgen receptor. The scientists hope the newly found connection will aid in better understanding the development of prostate cancer and lead to new drugs against the disease.

Prostate :: Octogenarians are not too old for cancer surgery

Mayo Clinic Cancer Center researchers have found that a radical prostatectomy can be a viable option for select octogenarian patients. The findings, which run counter the conventional practice of generally avoiding surgeries for individuals over 80 years old solely based on age, are available today in Urology.

Prostate Cancer :: Scientists design a PSA-activated protoxin that kills prostate cancer

Scientists have found a way of using a protein made by prostate cancer to target and kill the cancer cells themselves. In preliminary studies the new therapy affected only the prostate, without causing damage to other healthy tissues, and now it is being tested in a phase I clinical trial, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague on Friday.

Prostate Cancer :: Largest PSA Bounce Study Eases Worry of Prostate Cancer Returning

Prostate cancer patients who have a temporary rise in their prostate specific antigen (PSA) levels after radiation therapy – called a PSA bounce – are not at an increased risk of their cancer coming back any more than those who don?t have a temporary rise, according to the largest study of its kind presented November 8, 2006, at the American Society for Therapeutic Radiology and Oncology?s 48th Annual Meeting in Philadelphia.

Prostate Cancer :: ‘Muscle’ protein drives prostate cancer

Researchers at the Johns Hopkins Kimmel Cancer Center have for the first time implicated the muscle protein myosin VI in the development of prostate cancer and its spread.

Prostate Cancer :: Mayo Clinic Cancer Center Prostate SPORE Grant Renewed

Mayo Clinic Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer.

Prostate Cancer :: Men with prostate cancer avoid radiation due to misconceptions

Negative perceptions about radiation therapy can strongly influence a prostate cancer patient’s choice to avoid external beam radiation therapy, even though studies have proven the treatment to be as safe and effective as other treatments for the disease, including surgery, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology’s 48th Annual Meeting in Philadelphia.

Prostate Cancer :: More than 6 months of hormone therapy doesn’t help prostate cancer patients live longer

Prostate cancer patients treated with either radiation or surgery who use hormone therapy for longer than six months do not survive any longer than patients who use the treatment for a shorter amount of time, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology’s 48th Annual Meeting in Philadelphia.

Prostate Cancer :: IMRT versus 3D CRT for prostate cancer

New research findings show men have fewer long-term gastrointestinal side effects with intensity-modulated radiation therapy (IMRT) than with three-dimensional conformal radiation therapy (3D CRT) for prostate cancer treatment, despite the higher doses of radiation used in the IMRT group. These and other data, including long-term genitourinary side effects, were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

Prostate Cancer :: Hong Kong scientists identify cancer-blocking protein

Scientists in Hong Kong have identified a protein that can help suppress the growth of prostate cancer cells, the third most common cancer in men worldwide, and the finding might pave the way for the making of a new drug but not so soon.